Recently, Beijing Polyseq Biotechnology Co., Ltd. (hereinafter referred to as "Polyseq Biotechnology") and Wuhan Beina Medical Technology Co., Ltd. (hereinafter referred to as "Beina Medical") held a signing ceremony, officially reaching a comprehensive strategic cooperation on "clinical application promotion and customized development of nanopore sequencers".
At the signing ceremony, Wang Daqian, General Manager of Polyseq Biotechnology (first from the left), and Wang Jun, General Manager of Beina Medical (first from the right)
Dr. Wang Daqian, General Manager of Polyseq Biotechnology, and Dr. Wang Jun, General Manager of Beina Medical, signed the agreement on behalf of both parties.
Both parties stated that Polyseq Biotechnology has demonstrated strong research and development capabilities and product delivery capabilities in nanopore sequencing equipment in the past few years. Based on the solid underlying technology and rapid iteration capability of Polyseq Biotechnology in the field of nanopore sequencing, as well as the profound accumulation of Beina Medicine in the clinical translation of nanopore sequencing, a strong alliance is formed to jointly explore the multi scenario application and commercial expansion of domestic nanopore sequencing platforms in the field of medical testing. Both sides had in-depth exchanges on the future prospects, technological development directions, and technological optimization of nanopore sequencing technology.
Dr. Wang Daqian, General Manager of Polyseq Biotechnology, stated that
Polyseq Biotechnology focuses on the research and development of upstream nanopore sequencing platforms and supporting consumables, and does not enter the mid to downstream application fields. We welcome partners to develop applications and expand the market based on Polyseq Biotechnology's open sequencing platform. During this process, Polyseq Biotechnology treats every partner fairly, protects their intellectual property and trade secrets, and is committed to creating greater value for our partners.
Beina Medicine is an excellent representative of the clinical application transformation of nanopore sequencing technology, and Polyseq Biotechnology attaches great importance to its deep strategic cooperation with Beina Medicine. We believe that through deep coupling, complementary advantages, collaborative innovation, and vertical integration of sequencing platforms and applications, we can jointly promote nanopore technology to a wider range of application fields, benefiting the Chinese market.
Bena Medical General Manager Wang Jun stated that
Beina Medical has been focusing on the clinical application transformation and molecular diagnostic reagent development of nanopore sequencing technology. Currently, a series of clinical diagnostic products have been launched around the three major fields of pathogenic microorganisms, tumors, and genetics. We have reached a strategic cooperation with Polyseq Biotechnology for mutual benefit and win-win results. We believe that with the support of an excellent domestic nanopore sequencing platform, we can better achieve full process autonomy and controllability in clinical applications, jointly promote nanopore sequencing from the laboratory to clinical and industrialization, and provide more efficient and flexible solutions for disease diagnosis and treatment.
Previously, Beina Medical had conducted multiple rounds of in-depth testing on the PolyseqOne sequencing platform of Polyseq Biotechnology, and PolyseqOne of Polyseq Biotechnology performed excellently in multiple indicators such as accuracy and data output.
Actual test data shows that a single PolyseqOne chip from Polyseq Biotech can stably produce 1Gb of data within 2 hours, and even after 9 washes, it can still maintain a high number of active pores and stable data output, greatly reducing the cost of customer chip usage. For the real pathogen samples tested by customers, the accuracy of PolyseqOne sequencing by Polyseq Biotechnology has always remained at the median Q16 level, and the pathogen detection rate meets clinical needs.
In addition, with simple and fast library construction and sequencing operations, as well as comprehensive services such as installation, training, and after-sales service, and deep collaboration in experimental method optimization and process customization, the PolyseqOne sequencing platform of Polyseq Biotechnology well meets various needs of customers for medical clinical testing. The excellent performance of the PolysseqOne sequencing platform has laid a solid foundation for the strategic cooperation between the two parties.
As of recently, Polyseq Biotechnology has successively released nanopore sequencing platforms such as PolyseqOne and PolyseqHive, and has cooperated with multiple institutions to complete the installation and landing of over 100 sequencing machines.
In the next stage, Polyseq Biotechnology will launch a sequencing platform and chip with a single sequencing data output greater than 100Gb, a sequencing chemistry system with 99% (Q20) accuracy, and deepen cooperation with scientific research and enterprise partners in methylation, RNA sequencing, and other directions to provide customers with more diverse, flexible, and customizable choices.
About Bena Medical
Wuhan Beina Medical Technology Co., Ltd. (referred to as "Beina Medical"), as a wholly-owned subsidiary of Wuhan Beina Technology Co., Ltd., was officially established in 2022. Bena Medical has established Wuhan Bena Medical Laboratory, which has obtained a medical institution practice license and can provide professional and accurate testing services for clinical practice. Bena Medical focuses on the clinical application transformation of nanopore sequencing technology and the development of molecular diagnostic reagents. Currently, a series of clinical diagnostic products have been launched around the three major fields of pathogenic microorganisms, tumors, and genetics.
About Translation Biology
Beijing Polyseq Biotechnology Co., Ltd. was established in November 2021, focusing on the research and commercialization of biological nanopore gene sequencing systems. Based on the principle of nanopore gene sequencing, the company constructs a sequencing chemistry system with independent intellectual property rights, using a newly independently analyzed biological nanopore atomic horizontal structure as the foundation, combined with nucleic acid chemistry, protein engineering, etc; Build a high-level sequencing platform using integrated circuit chips, software engineering, and deep learning algorithms; Developing high-precision, high-throughput, long read, low-cost nanopore sequencers and supporting reagents and consumables, enabling gene sequencing technology to enter medical institutions at all levels, benefiting the public, safeguarding the lives and health of the people, and meeting the needs of precision medicine in the era of big data.
